Breast
cancer is defined as out of control growth of cells in the breast
which have the ability to form a tumor or lump. These lumps or tumors
in the breast are easily detectable through an X-ray. Breast cancer
can form in the duct, nipple, glands, or other tissues. The most
common types of breast cancer are invasive lobular carcinoma,
invasive ductal carcinoma, ductal carcinoma in situ, triple negative
breast cancer, metastatic breast cancer, and less common being
lymphomas or sarcomas and inflammatory breast cancer.
Download
exclusive Sample of this report:
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=36128
Breast
cancer is one of the most common cancers among woman globally and a
major cause of mortality. Therefore, early detection is needed for
these diseases. Breast cancer is more prevalent in the industrialized
countries due to modernized lifestyle; however, the rate of incidence
is expected to rise in developing countries.
According
to the WHO, in 2012, round 1.7 million new cases of breast cancer
were diagnosed globally. According to the American Cancer Society,
breast cancer accounts for 1 in 8 cancers diagnosed in women in the
U.S. Symptoms of breast cancer may or may not appear in women. Hence,
regular screening is necessary to prevent the malignancy. Breast
cancer screening is a regular examination to detect breast cancer.
Early detection could ensure timely treatment of patients, thereby
reducing the mortality rate. Breast cancer screening generally
involves mammography, MRI scan, or ultrasound. Mammography is
considered to be the best screening test for the detection of breast
cancer.
A
rise in the standard of living and educational opportunities for
women had resulted in late first pregnancy with limited lactation
period indirectly leading to fluctuating hormone levels and high risk
of breast cancer. Probability of breast cancer increases with age.
Hence, rise in geriatric population is a major factor for increase in
incidence of breast cancer.
Rise
in incidence of breast cancer, growing awareness about breast cancer
screening tests, government initiatives for breast cancer screening
programs, technical advancements in breast imaging technologies,
implementation of national level programs by the government for early
diagnosis are the major factors driving the market.
Based
on diagnostic test type, the global
breast cancer screening tests market can be segmented into
blood marker tests, imaging test, genetic test, and
immunohistochemistry test. Imaging test is the most commonly used
test for the screening of breast cancer. The segment can be further
divided into mammography, MRI screening test, molecular breast
imaging test, PET scan, and ultrasound. Mammography is the most
common test used for the detection of breast cancer. Genetic test can
be sub-segmented into fluorescence in situ hybridization and HER gene
test. In most developed countries, mammography is included in the
breast screening program making it the most popular breast cancer
screening test.
In
terms of end-user, the global breast screening tests market can be
segmented into hospitals, diagnostic centers, cancer institutes, and
research laboratories. National breast cancer screening awareness
programs and awareness about genetic transfer of breast cancer boost
the growth of the diagnostic centers segment.
In
terms of region, the global breast cancer screening market can be
segmented into North America, Europe, Asia Pacific, Latin America,
and Middle East & Africa. Countries such as United States,
Germany, United Kingdom, Japan and China capture the maximum share
for the population with higher probability of breast cancer. In 2016,
these countries accounted for over 60% share of the global North
America is anticipated to hold major market share, as 70% of women in
the U.S. undergo mammography. Germany is likely to dominate the
market in Europe, due to advanced health care infrastructure and
government supported screening programs. Availability of screening
services in private health care and diagnostic centers is expected to
drive the market in developing countries such as India.
Key
players in the global breast cancer screening tests market are A&G
Pharmaceutical, Inc., Biocrates Life Sciences AG, Metabolomic
Technologies, Inc., Myriad Genetics, Siemens Healthcare Diagnostics,
Inc., OncoCyte Corporation, POC Medical Systems, Inc., Hologic, Inc.,
Provista Diagnostics, Inc., and BioTime, Inc.
No comments:
Post a Comment